What changed from existing technology?
This study looked at how well the immune system of people with weak immunity responds to a COVID-19 antibody treatment, to help decide when to use it.
This is the first study to evaluate cellular responses alongside serology to guide monoclonal antibody prophylaxis in immunocompromised individuals.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
ophylactic treatment administration. Immunocompromised patients are highly susceptible to viral infections and often have suboptimal humoral responses to SARS
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This approach could help clinicians decide when to administer tixagevimab/cilgavimab (Evusheld) to immunocompromised patients based on their cellular immune response and serology.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.